Comparative Pharmacology
Head-to-head clinical analysis: ADASUVE versus MILPROSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADASUVE versus MILPROSA.
ADASUVE vs MILPROSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine (the active ingredient in ADASUVE) is a dibenzoxazepine antipsychotic agent that acts primarily as a dopamine D2 receptor antagonist. It also exhibits affinity for serotonin 5-HT2A, 5-HT2C, and histamine H1 receptors, and to a lesser extent, alpha-adrenergic and muscarinic receptors. The exact mechanism of its antipsychotic effect is thought to involve dopamine and serotonin receptor blockade.
Milprosa is a progesterone receptor agonist that induces and maintains endometrial receptivity, inhibits uterine contractions, and suppresses gonadotropin release.
Inhalation: 10 mg as a single dose via oral inhalation up to a maximum of 2 doses within a 24-hour period, each dose separated by at least 2 hours. For agitation associated with schizophrenia or bipolar I disorder.
MILPROSA is not a recognized drug; assuming a typo for milrinone? If milrinone: IV loading dose 50 mcg/kg over 10 minutes, then continuous IV infusion 0.375-0.75 mcg/kg/min.
None Documented
None Documented
Mean terminal half-life of loxapine is 6-8 hours; active metabolite 7-hydroxyloxapine (amoxapine) has half-life of ~30 hours. Clinically, steady state achieved within 3-5 days.
14 hours (range 10–18); prolonged in renal impairment (up to 40 hours)
Primarily renal (30-40% as unchanged drug and metabolites; ~50% as loxapine metabolites), with minor biliary/fecal elimination (<10%).
Renal (70% unchanged, 20% as inactive metabolites); fecal (10%)
Category C
Category C
Antipsychotic
Antipsychotic